Mylan to acquire Cold-EEZE from ProPhase

10 January 2017 - Deborah Wilkes

Archived

Mylan is acquiring global rights to the Cold-EEZE OTC brand from ProPhase Labs in a deal worth USD50 million. The generics giant intends to continue boosting its global OTC presence through further product acquisitions.

Click tags below for more information on topics:

Mylan

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: